Work

パロキセチンによる中断時発現症状の発現率の個人差に関する臨床的・薬理遺伝学的検討

Year: 2014
Type: article
Study design: Observational Study
Abstract: Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life.However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment.In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome.A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine.Paroxetine discontinuation syndrome was found in 35 .7 % of the patients by direct interview.Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication.Patients who had the < 1019 C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the < 1019 G homozygote (nominal P = 0 .0423) of the serotonin 1 A receptor gene.However, this result did not remain significant after the Bonferroni correction for multiple comparisons.The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(< 1019)G polymorphism of the serotonin 1 A receptor gene may be related to the occurrence of the syndrome.
Institution: Fukuoka University
Language: Japanese
Open Access status: green
OpenAlex ID: W7208303179
FWCI:
Cites: 14
Cited by:
Related to: 10